Daiichi Sankyo (4568.T): Roundtable meeting with management: Many events to look forward to

Research evidence excerpt

Daiichi Sankyo (4568.T): Roundtable meeting with management: Many events to look forward to

Flash |

09 Jul 2026 20:22:10 ET │ 10 pages

Daiichi Sankyo (4568.T)

Roundtable meeting with management: Many events to look forward to

CITI’S TAKE

We hosted a roundtable meeting with management primarily for overseas

Buy investors. Management discussed the Avanzar trial and said it expects to

Price (09 Jul 26 15:30) ¥2,733.0 have topline results within the year as scheduled. Results are unknown at

present, with the delay attributed to the time required for event Target price ¥4,800.0

occurrence. While no new information emerged, we believe management Expected share price return 75.6%

maintains high expectations. With first-line trial results for TL-07, TL-08, Expected dividend yield 3.7%

and TL-10 to follow, we feel the rich event pipeline will drive renewed Expected total return 79.3%

attention to the stock. Regarding CMO loss compensation, negotiations Market Cap ¥4,973,112M

with CMOs on manufacturing capacity returns will occur during the fiscal

US$30,817M year, making Q3/Q4 the likely timing for compensation expenses. There

should be no negative impact on Q1 earnings.

Management presented three ideas to improve cost efficiency in the medium-term Hidemaru YamaguchiAC

plan. First, the global ERP rollout launched in Europe last year will deploy in the US +81-3-6776-4620

this year and Japan next year. Second, the company is aggressively introducing AI in hidemaru.yamaguchi@citi.com

HR, R&D, and other areas. For R&D, it appears AI could contribute significantly in

clinical trial site selection, trial data summaries, and report generation, and

management is looking into this further. The third idea is marketing organization

efficiency improvements.